Abstract
Pancreatic fistula remains a frequent and serious complication following pancreatic surgery. The incidence ranges from 10-20% in most series, with pancreatic texture being the most common predictor of the complication. There is little level 1 evidence to support any potential measures to reduce the incidence of pancreatic fistula.
MeSH terms
-
Gastrointestinal Agents / therapeutic use
-
Humans
-
Octreotide / therapeutic use
-
Pancreatectomy / adverse effects
-
Pancreatectomy / methods
-
Pancreatic Fistula / epidemiology
-
Pancreatic Fistula / etiology
-
Pancreatic Fistula / prevention & control*
-
Pancreatic Fistula / therapy
-
Pancreaticoduodenectomy / adverse effects*
-
Pancreaticoduodenectomy / methods
-
Stents
Substances
-
Gastrointestinal Agents
-
Octreotide